Study of BMS-650032 With Peginterferon Alfa-2a Plus Ribavirin
Status:
Completed
Trial end date:
2012-10-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to identify one or more doses of BMS-650032 that, when used in
combination with pegylated-interferon alpha and ribavirin are safe and demonstrate sufficient
activity against hepatitis C virus (Genotypes 1 and 4).